Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.

Breast Cancer Research and Treatment
Arkadiusz Z DudekRuth M O'Regan

Abstract

TTC-352 is a selective human estrogen receptor (ER) partial agonist developed for treatment of hormone-refractory ER + breast cancer. This was an accelerated dose escalation study with the primary endpoint of maximum tolerated dose that evaluated five dose levels of TTC-352 in breast cancer progressing after at least two lines of hormonal therapy including one in combination with a CDK4/6 inhibitor. The secondary objectives were to determine treatment tolerability, pharmacokinetics of TTC-352, best response, progression-free survival (PFS), and PKCα expression in tumors. The study enrolled 15 patients. No dose-limiting toxicity was observed. Patients experienced the following grade 3 toxicities: asymptomatic pulmonary embolism, diarrhea, aspartate transaminase elevation, and myalgia, and one grade 4 toxicity of gamma glutamyltransferase elevation. Pharmacokinetic half-life was 7.6-14.3 h. The intra- and inter-individual variability for AUC0-∞ hampered assessment of the relationship between dose and AUC0-∞. Median PFS was 58 days (95% CI = 28,112). Higher PKCα expression in tumor stroma was associated with a trend toward longer PFS. TTC-352 demonstrates safety and early clinical evidence of antitumor activity against heavily pre...Continue Reading

References

Apr 1, 1985·American Journal of Clinical Oncology·H MatelskiT Zipoli
Jul 9, 2002·Breast Cancer Research : BCR·James N Ingle
Aug 7, 2002·Clinical Pharmacokinetics·Michael S RobertsMichael Weiss
Sep 25, 2003·Endocrine-related Cancer·H J Mackay, C J Twelves
Oct 15, 2008·The Journal of Pathology·F PonténM Uhlen
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 20, 2010·Molecular Cancer·Gry Kalstad LønneChrister Larsson
May 21, 2010·Clinical Pharmacokinetics·Neal M DaviesJaime A Yáñez
Apr 14, 2012·International Journal of Breast Cancer·Debra A TonettiJohn S Coon
May 6, 2014·Frontiers in Oncology·Julie A WallaceMichael C Ostrowski
Sep 11, 2014·Molecular Cancer Therapeutics·Mary Ellen MolloyDebra A Tonetti
Jul 8, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·Rowan T ChlebowskiGarnet L Anderson
Nov 26, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G ZucchiniS J Howell
Dec 19, 2015·Journal of Medicinal Chemistry·Rui XiongGregory Rj Thatcher
Nov 28, 2016·Maturitas·Herjan J T Coelingh BenninkJos Thijssen

❮ Previous
Next ❯

Citations

Oct 9, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ozge SaatciOzgur Sahin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.